Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts.

Although the difference in OS between sorafenib plus TACE and TACE alone was 5.4 months [ 73 ], it did not reach statistical significance; however, it was deemed to be clinically meaningful.

also in 111,027 other papers